FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384821164> ?p ?o ?g. }

• W4384821164 endingPage "3675" @default.
• W4384821164 startingPage "3675" @default.
• W4384821164 abstract "Patients with breast cancer undergoing chemotherapy are susceptible to prolonged and severe neutropenia. Multiple biosimilars of long-acting granulocyte colony-stimulating factors (LA-G-CSFs) have been newly developed to prevent this disease. Nonetheless, which LA-G-CSF regimen has the optimal balance of efficacy and safety remains controversial. Moreover, there is a lack of evidence supporting clinical decisions on LA-G-CSF dose escalation in poor conditions. PubMed, Embase, Cochrane Library, Web of Science, and several Chinese databases were searched (December 2022) to collect randomized controlled trials (RCTs) about LA-G-CSFs preventing chemotherapy-induced neutropenia in breast cancer patients. No restrictions were imposed on language. A Bayesian network meta-analysis was performed. We assessed the incidence of severe neutropenia (SN) and febrile neutropenia (FN), the duration of SN (DSN), and the absolute neutrophil account recovery time (ANCrt) for efficacy, while the incidence of severe adverse events (SAE) was assessed for safety. The study was registered in PROSPERO (CRD42022361606). A total of 33 RCTs were included. Our network meta-analysis demonstrated that lipegfilgrastim 6 mg and eflapegrastim 13.2 mg outperformed other LA-G-CSFs with high efficacy rates and few safety concerns (SUCRA of lipegfilgrastim 6 mg: ANC rt 95.2%, FN 97.4%; eflapegrastim 13.2 mg: FN 87%, SN 89.3%). Additionally, 3.6 mg, 4.5 mg, 6 mg, and 13.2 mg dosages all performed significantly better than 1.8 mg in reducing the duration of SN (3.6 mg: DSN, SMD -0.68 [-1.13, -0.22; moderate]; 4.5 mg: -0.87 [-1.57, -0.17; low]; 6 mg: -0.89 [-1.49, -0.29; moderate]; 13.2 mg: -1.02 [1.63, -0.41; high]). Increasing the dosage from the guideline-recommended 6 mg to 13.2 mg can reduce both the duration and incidence of SN (SMD -0.13 [-0.24 to -0.03], RR 0.65 [0.43 to 0.96], respectively), with no significant difference in SAE. For patients with breast cancer, lipegfilgrastim 6 mg and eflapegrastim 13.2 mg might be the most effective regimen among LA-G-CSFs. Higher doses of LA-G-CSF may enhance efficacy without causing additional SAEs." @default.
• W4384821164 created "2023-07-21" @default.
• W4384821164 creator A5000944040 @default.
• W4384821164 creator A5015033018 @default.
• W4384821164 creator A5030294951 @default.
• W4384821164 creator A5031255136 @default.
• W4384821164 creator A5038859783 @default.
• W4384821164 creator A5046887099 @default.
• W4384821164 creator A5071201067 @default.
• W4384821164 creator A5088150060 @default.
• W4384821164 date "2023-07-19" @default.
• W4384821164 modified "2023-09-30" @default.
• W4384821164 title "Assessing the Optimal Regimen: A Systematic Review and Network Meta-Analysis of the Efficacy and Safety of Long-Acting Granulocyte Colony-Stimulating Factors in Patients with Breast Cancer" @default.
• W4384821164 cites W1546909751 @default.
• W4384821164 cites W1828514487 @default.
• W4384821164 cites W1955327477 @default.
• W4384821164 cites W1963900518 @default.
• W4384821164 cites W1967385770 @default.
• W4384821164 cites W1972469059 @default.
• W4384821164 cites W1995429954 @default.
• W4384821164 cites W1998689347 @default.
• W4384821164 cites W2000487326 @default.
• W4384821164 cites W2003088626 @default.
• W4384821164 cites W2014576677 @default.
• W4384821164 cites W202042235 @default.
• W4384821164 cites W2036450045 @default.
• W4384821164 cites W2048982730 @default.
• W4384821164 cites W2050242888 @default.
• W4384821164 cites W2077238328 @default.
• W4384821164 cites W2077781144 @default.
• W4384821164 cites W2100082529 @default.
• W4384821164 cites W2106207219 @default.
• W4384821164 cites W2110534467 @default.
• W4384821164 cites W2110631033 @default.
• W4384821164 cites W2110645520 @default.
• W4384821164 cites W2111408591 @default.
• W4384821164 cites W2113144077 @default.
• W4384821164 cites W2115170812 @default.
• W4384821164 cites W2121985645 @default.
• W4384821164 cites W2127838945 @default.
• W4384821164 cites W2150529573 @default.
• W4384821164 cites W2164788594 @default.
• W4384821164 cites W2169203358 @default.
• W4384821164 cites W2169403306 @default.
• W4384821164 cites W2199775161 @default.
• W4384821164 cites W2331170460 @default.
• W4384821164 cites W2336901813 @default.
• W4384821164 cites W2341557816 @default.
• W4384821164 cites W2411253176 @default.
• W4384821164 cites W2528477403 @default.
• W4384821164 cites W2609294275 @default.
• W4384821164 cites W2772503094 @default.
• W4384821164 cites W2883735636 @default.
• W4384821164 cites W2888594123 @default.
• W4384821164 cites W2890474078 @default.
• W4384821164 cites W2915282535 @default.
• W4384821164 cites W2920298278 @default.
• W4384821164 cites W2940114236 @default.
• W4384821164 cites W2943483493 @default.
• W4384821164 cites W2971330481 @default.
• W4384821164 cites W2986986936 @default.
• W4384821164 cites W3013624574 @default.
• W4384821164 cites W3029874704 @default.
• W4384821164 cites W3040325970 @default.
• W4384821164 cites W3044619557 @default.
• W4384821164 cites W3083679990 @default.
• W4384821164 cites W3118615836 @default.
• W4384821164 cites W3128646645 @default.
• W4384821164 cites W324244878 @default.
• W4384821164 cites W4280522908 @default.
• W4384821164 cites W4283029993 @default.
• W4384821164 cites W4311613428 @default.
• W4384821164 cites W4313562032 @default.
• W4384821164 cites W68218898 @default.
• W4384821164 doi "https://doi.org/10.3390/cancers15143675" @default.
• W4384821164 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37509336" @default.
• W4384821164 hasPublicationYear "2023" @default.
• W4384821164 type Work @default.
• W4384821164 citedByCount "0" @default.
• W4384821164 crossrefType "journal-article" @default.
• W4384821164 hasAuthorship W4384821164A5000944040 @default.
• W4384821164 hasAuthorship W4384821164A5015033018 @default.
• W4384821164 hasAuthorship W4384821164A5030294951 @default.
• W4384821164 hasAuthorship W4384821164A5031255136 @default.
• W4384821164 hasAuthorship W4384821164A5038859783 @default.
• W4384821164 hasAuthorship W4384821164A5046887099 @default.
• W4384821164 hasAuthorship W4384821164A5071201067 @default.
• W4384821164 hasAuthorship W4384821164A5088150060 @default.
• W4384821164 hasBestOaLocation W43848211641 @default.
• W4384821164 hasConcept C121608353 @default.
• W4384821164 hasConcept C126322002 @default.
• W4384821164 hasConcept C141071460 @default.
• W4384821164 hasConcept C143998085 @default.
• W4384821164 hasConcept C168563851 @default.
• W4384821164 hasConcept C197934379 @default.
• W4384821164 hasConcept C2776478404 @default.
• W4384821164 hasConcept C2776694085 @default.
• W4384821164 hasConcept C2777063308 @default.

• next